Hochpräzise Basen-Editierungstherapie zeigt dauerhafte VOC-freie Wirksamkeit und günstige Sicherheit bei Sichelzellanämie

Data ReadoutpositiveCS-206Positive

AI Analysis

Summary

CorrectSequence Therapeutics reported positive 15-month follow-up data for CS-206, showing sustained vaso-occlusive crisis-free efficacy and favorable safety profile in sickle cell anemia patients.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

15-month follow-up data showing sustained VOC-free efficacy and favorable safety

Importance:7/10

Sentiment:

0.80

base editingsickle cell diseaseclinical datagene therapyvaso-occlusive crisis

Read the original article

Published by PR Newswire Biotech on June 3, 2026 1:16 PM

Read Original